Mbwasi Romuald, Mapunjo Siana, Wittenauer Rachel, Valimba Richard, Msovela Kelvin, Werth Brian J, Khea Akida Msallah, Nkiligi Emmanuel Alphonce, Lusaya Edgar, Stergachis Andy, Konduri Niranjan
St. John's University of Tanzania, Dodoma, Tanzania.
Ministry of Health, Community Development, Gender, Elderly, and Children, Dodoma, Tanzania.
Front Pharmacol. 2020 Oct 30;11:585553. doi: 10.3389/fphar.2020.585553. eCollection 2020.
Surveillance of antimicrobial consumption is essential to the national action plan for antimicrobial resistance (AMR) as stipulated in the Global Action Plan on AMR and the Tanzanian National Action Plan on AMR. Given the paucity of antimicrobial consumption data in sub-Saharan Africa region, the objective of this study was to measure antimicrobial consumption in Tanzania. From 2017 to 2019, data on all antimicrobials imported into Tanzania were obtained from the Tanzania Medicines and Medical Devices Authority Data, augmented with purchasing data from the Medical Stores Department and data from local manufacturers. Data were collected and analyzed in accordance with the World Health Organization Anatomical Therapeutic Chemical and defined daily doses (DDD) methodology. The average DDD per 1,000 inhabitants per day (DDD/1,000/D) for all antimicrobials was 80.8 ± 39.35. The DDD/1,000/D declined from 136.41 in 2017 to 54.98 in 2018 and 51.02 in 2019. Doxycycline, amoxicillin, and trimethoprim-sulfamethoxazole were the most frequently consumed antibiotics during these years, accounting for 20.01, 16.75, and 12.42 DDD/1,000/D, respectively. The majority of antimicrobial consumption in Tanzania occurred in the private sector, with the proportion of private-sector antibiotic consumption increasing annually from 2017 to 2019. Based on AWaRe classification >90% of antimicrobial consumption was Access class medications, with Watch and Reserve class medications accounting for <10% and <1%, respectively. The private sector use of antimicrobials is significantly increasing and should be carefully monitored in accordance with national policies. Future work is necessary to increase reporting of antimicrobial consumption patterns in sub-Saharan Africa.
正如《抗微生物药物耐药性全球行动计划》和《坦桑尼亚抗微生物药物耐药性国家行动计划》所规定的,监测抗菌药物消费对于国家抗微生物药物耐药性(AMR)行动计划至关重要。鉴于撒哈拉以南非洲地区抗菌药物消费数据匮乏,本研究的目的是测量坦桑尼亚的抗菌药物消费量。2017年至2019年,从坦桑尼亚药品和医疗器械管理局数据中获取了所有进口到坦桑尼亚的抗菌药物数据,并补充了医疗用品部门的采购数据和当地制造商的数据。数据按照世界卫生组织解剖治疗化学分类和限定日剂量(DDD)方法进行收集和分析。所有抗菌药物的人均每日平均限定日剂量(DDD/1000/D)为80.8±39.35。DDD/1000/D从2017年的136.41降至2018年的54.98和2019年的51.02。在这些年中,多西环素、阿莫西林和复方新诺明是最常消费的抗生素,分别占20.01、16.75和12.42 DDD/1000/D。坦桑尼亚的大部分抗菌药物消费发生在私营部门,2017年至2019年私营部门抗生素消费比例逐年增加。根据AWaRe分类,>90%的抗菌药物消费为可及类药物,监测类和储备类药物分别占<10%和<1%。私营部门对抗菌药物的使用显著增加,应根据国家政策进行仔细监测。未来有必要增加撒哈拉以南非洲地区抗菌药物消费模式的报告。